Ascletis Pharma
Ascletis’ ASC47 Combo with Semaglutide Shows 56% Greater Weight Loss, Better GI Safety
Ascletis Pharma reported topline results from its ASC47-103 study in obesity: ASC47 plus semaglutide enhanced weight loss by up to 56.2% versus semaglutide alone, reduced LDL-C, improved GI tolerability, and showed reduced rebound post-treatment.